FindTrial
Sign In

Investigation of the safety and efficacy of eszopiclone in insomnia patients

Investigation of the safety and efficacy of eszopiclone in insomnia patients

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222867
Enrollment
3300
Registered
2015-05-27
Start date
2015-05-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

investigational material(s) Generic name etc : LUNESTA INN of investigational material : Eszopiclone Therapeutic category code : 112 Hypnotics and sedatives, antianxietics Dosage and Administration fo

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) insomnia patients who did not take eszopiclone before assessment 2) patients who receive assessment by using sleep questionaries

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Assessment of overall improvement The investigators will interview the patients regarding sleep improvement at 4 weeks after first dose or discontinuation relative to predose, and select the appropriate answer. 1. Improved 2. Unchanged 3. Worse 4. Indiscernible—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026